# US 2013/0280339 A1 · Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280339 A1
- Document ID: US20130280339A1
- Status: Published application
- Kind: A1
- Application number: 13/903,249
- Filed: 2013-05-28
- Published: 2013-10-24
- Earliest claimed: 2008-06-16
- Assignees: BIND Therapeutics, Inc.
- Applicants: BIND Therapeutics, Inc.
- Inventors: Stephen E. Zale; Greg Troiano; Mir Mukkaram Ali; Jeff Hrkach; James Wright
- Web page: https://patentgrep.com/patent/US20130280339A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61J 3/00: Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4355: the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/6915: {the form being a liposome with polymerisable or polymerized bilayer-forming substances, e.g. polymersomes}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- C07C 59/08: Lactic acid
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

## Claims

### Claim 1

A therapeutic nanoparticle comprising:
about 4 to about 25 weight percent of an anti-cancer agent, wherein the anti-cancer agent is a kinase inhibitor;
about 10 to about 99 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer, wherein said poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa; and
wherein the hydrodynamic diameter of the therapeutic nanoparticle is about 60 to about 140 nm; and wherein the therapeutic nanoparticle releases less than 10% of the anti-cancer agent over about one minute when placed in a phosphate buffer solution at 37° C.

### Claim 2 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the hydrodynamic diameter is about 70 to about 120 nm.

### Claim 3 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the therapeutic nanoparticle substantially retains the anti-cancer agent for at least 5 days at 25° C.

### Claim 4 (depends on 1)

The therapeutic nanoparticle of claim 1, comprising about 40 to about 90 weight percent diblock poly(lactic) acid-poly(ethylene)glycol copolymer.

### Claim 5 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the particle releases less than about 5% of the anti-cancer agent over 1 hour when placed in a phosphate buffer solution at room temperature.

### Claim 6 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the particle releases less than about 10% of the anti-cancer agent over 24 hours when placed in a phosphate buffer solution at room temperature.

### Claim 7 (depends on 4)

The therapeutic nanoparticle of claim 4, wherein said poly(ethylene)glycol has a number average molecular weight of about 5 kDa.

### Claim 8 (depends on 1)

A method of treating prostate, breast or hematological tissue cancer comprising administering to a patient in need thereof an effective amount of the therapeutic nanoparticle of claim 1.

### Claim 9

A pharmaceutical composition comprising:
a plurality of polymeric nanoparticles each comprising about 5 to about 30 weight percent of an anti-cancer agent; about 70 to about 99 weight percent of a biocompatible polymer, wherein the biocompatible polymer is selected from the group consisting of: a) poly(lactic) acid-poly(ethylene)glycol copolymer, wherein said poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 16 kDa and poly(ethylene)glycol having a number average molecular weight of about 5 kDa; and b) a combination of a) and poly(lactic) acid; and
a pharmaceutically acceptable excipient;
wherein the hydrodynamic diameter of the polymeric nanoparticle is about 70 to about 130 nm; and wherein the polymeric nanoparticle releases less than 10% of the anti-cancer agent over about one minute when placed in a phosphate buffer solution at 37° C.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the anti-cancer agent is a kinase inhibitor.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, wherein the pharmaceutically acceptable excipient is sucrose.

### Claim 12

A pharmaceutical composition comprising:
a plurality of polymeric nanoparticles each having a hydrodynamic diameter of about 60 nm to about 140 nm and comprising about 3 to about 40 weight percent of an anti-cancer agent, wherein said anti-cancer agent is a kinase inhibitor; about 10 to about 99 weight percent of a diblock poly(lactic)acid-poly(ethylene)glycol copolymer comprising poly(lactic)acid having a number average molecular weight of about 15 to about 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa, and
a saccharide;
wherein said nanoparticles are stable for at least 3 days when held at 25° C. in said composition.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the saccharide is sucrose.
